Current  ||| S:0 E:8 ||| JJ
status  ||| S:8 E:15 ||| NN
of  ||| S:15 E:18 ||| IN
drug-eluting  ||| S:18 E:31 ||| JJ
stents  ||| S:31 E:38 ||| NN
and  ||| S:38 E:42 ||| CC
drug-eluting  ||| S:42 E:55 ||| JJ
balloons  ||| S:55 E:64 ||| NNS
in  ||| S:64 E:67 ||| IN
patients  ||| S:67 E:76 ||| NNS
with  ||| S:76 E:81 ||| IN
stable  ||| S:81 E:88 ||| JJ
coronary  ||| S:88 E:97 ||| JJ
artery  ||| S:97 E:104 ||| NN
disease--an  ||| S:104 E:116 ||| JJ
expert  ||| S:116 E:123 ||| NN
consensus  ||| S:123 E:133 ||| NN
document  ||| S:133 E:142 ||| NN
of  ||| S:142 E:145 ||| IN
the  ||| S:145 E:149 ||| DT
Association  ||| S:149 E:161 ||| NNP
for  ||| S:161 E:165 ||| IN
Percutaneous  ||| S:165 E:178 ||| NNP
Cardiovascular  ||| S:178 E:193 ||| NNP
Interventions  ||| S:193 E:207 ||| NNP
and  ||| S:207 E:211 ||| CC
Polish  ||| S:211 E:218 ||| NNP
Cardiac  ||| S:218 E:226 ||| NNP
Society  ||| S:226 E:234 ||| NNP
Despite  ||| S:234 E:242 ||| IN
a  ||| S:242 E:244 ||| DT
dramatic  ||| S:244 E:253 ||| JJ
reduction  ||| S:253 E:263 ||| NN
in  ||| S:263 E:266 ||| IN
restenosis  ||| S:266 E:277 ||| NN
and  ||| S:277 E:281 ||| CC
target  ||| S:281 E:288 ||| NN
vessel  ||| S:288 E:295 ||| NN
revascularisation  ||| S:295 E:313 ||| NN
rates  ||| S:313 E:319 ||| NNS
by  ||| S:319 E:322 ||| IN
drug  ||| S:322 E:327 ||| NN
eluting  ||| S:327 E:335 ||| NN
stents  ||| S:335 E:342 ||| NNS
( ||| S:342 E:343 ||| -LRB-
DES ||| S:343 E:346 ||| NNP
) ||| S:346 E:347 ||| -RRB-
,  ||| S:347 E:349 ||| ,
conflicting  ||| S:349 E:361 ||| JJ
concerns  ||| S:361 E:370 ||| NNS
have  ||| S:370 E:375 ||| VBP
been  ||| S:375 E:380 ||| VBN
raised  ||| S:380 E:387 ||| VBN
over  ||| S:387 E:392 ||| IN
the  ||| S:392 E:396 ||| DT
risk  ||| S:396 E:401 ||| NN
for  ||| S:401 E:405 ||| IN
late  ||| S:405 E:410 ||| JJ
DES  ||| S:410 E:414 ||| NNP
thrombosis  ||| S:414 E:425 ||| NN
when  ||| S:425 E:430 ||| WRB
compared  ||| S:430 E:439 ||| VBN
to  ||| S:439 E:442 ||| TO
bare  ||| S:442 E:447 ||| JJ
metal  ||| S:447 E:453 ||| NN
stents ||| S:453 E:459 ||| NN
.  ||| S:459 E:461 ||| .
Certainly ||| S:461 E:470 ||| RB
,  ||| S:470 E:472 ||| ,
the  ||| S:472 E:476 ||| DT
heterogeneity  ||| S:476 E:490 ||| NN
of  ||| S:490 E:493 ||| IN
DES  ||| S:493 E:497 ||| NNP
results  ||| S:497 E:505 ||| NNS
from  ||| S:505 E:510 ||| IN
the  ||| S:510 E:514 ||| DT
introduction  ||| S:514 E:527 ||| NN
of  ||| S:527 E:530 ||| IN
a  ||| S:530 E:532 ||| DT
great  ||| S:532 E:538 ||| JJ
variety  ||| S:538 E:546 ||| NN
of  ||| S:546 E:549 ||| IN
new  ||| S:549 E:553 ||| JJ
DES  ||| S:553 E:557 ||| NNP
types  ||| S:557 E:563 ||| NNS
with  ||| S:563 E:568 ||| IN
diverse  ||| S:568 E:576 ||| JJ
efficacy  ||| S:576 E:585 ||| NN
and  ||| S:585 E:589 ||| CC
safety  ||| S:589 E:596 ||| NN
parameters ||| S:596 E:606 ||| NNS
.  ||| S:606 E:608 ||| .
Furthermore ||| S:608 E:619 ||| RB
,  ||| S:619 E:621 ||| ,
we  ||| S:621 E:624 ||| PRP
observe  ||| S:624 E:632 ||| VBP
a  ||| S:632 E:634 ||| DT
steady  ||| S:634 E:641 ||| JJ
increase  ||| S:641 E:650 ||| NN
in  ||| S:650 E:653 ||| IN
DES  ||| S:653 E:657 ||| NNP
availability  ||| S:657 E:670 ||| NN
without  ||| S:670 E:678 ||| IN
parallel  ||| S:678 E:687 ||| JJ
and  ||| S:687 E:691 ||| CC
robust  ||| S:691 E:698 ||| JJ
data  ||| S:698 E:703 ||| NNS
from  ||| S:703 E:708 ||| IN
randomised  ||| S:708 E:719 ||| JJ
clinical  ||| S:719 E:728 ||| JJ
trials ||| S:728 E:734 ||| NNS
.  ||| S:734 E:736 ||| .
Thus ||| S:736 E:740 ||| RB
,  ||| S:740 E:742 ||| ,
the  ||| S:742 E:746 ||| DT
postulated  ||| S:746 E:757 ||| JJ
class  ||| S:757 E:763 ||| NN
effect  ||| S:763 E:770 ||| NN
of  ||| S:770 E:773 ||| IN
DES  ||| S:773 E:777 ||| NNP
should  ||| S:777 E:784 ||| MD
be  ||| S:784 E:787 ||| VB
regarded  ||| S:787 E:796 ||| VBN
as  ||| S:796 E:799 ||| IN
non-obligatory ||| S:799 E:813 ||| JJ
.  ||| S:813 E:815 ||| .
This  ||| S:815 E:820 ||| DT
article  ||| S:820 E:828 ||| NN
is  ||| S:828 E:831 ||| VBZ
based  ||| S:831 E:837 ||| VBN
on  ||| S:837 E:840 ||| IN
110  ||| S:840 E:844 ||| CD
randomised  ||| S:844 E:855 ||| JJ
DES  ||| S:855 E:859 ||| NNP
trials  ||| S:859 E:866 ||| NNS
performed  ||| S:866 E:876 ||| VBN
on  ||| S:876 E:879 ||| IN
72  ||| S:879 E:882 ||| CD
305  ||| S:882 E:886 ||| CD
patients ||| S:886 E:894 ||| NNS
.  ||| S:894 E:896 ||| .
Current  ||| S:896 E:904 ||| JJ
status  ||| S:904 E:911 ||| NN
of  ||| S:911 E:914 ||| IN
DES  ||| S:914 E:918 ||| NNP
and  ||| S:918 E:922 ||| CC
guidelines  ||| S:922 E:933 ||| NNS
for  ||| S:933 E:937 ||| IN
DES  ||| S:937 E:941 ||| NNP
implantation  ||| S:941 E:954 ||| NN
in  ||| S:954 E:957 ||| IN
various  ||| S:957 E:965 ||| JJ
clinical  ||| S:965 E:974 ||| JJ
scenarios  ||| S:974 E:984 ||| NNS
were  ||| S:984 E:989 ||| VBD
discussed ||| S:989 E:998 ||| VBN
.  ||| S:998 E:1000 ||| .
